References
Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366:1945–53.
James C, Ugo V, Le Couédic J-P, Staerk J, Delhoummeau F, Flacount C, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature. 2005;434:1144–8.
Ohyashiki K, Aota Y, Akahane D, Gotoh A, Ohyashiki JH. JAK2V617F mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders. Leukemia. 2007;21:1097–9.
Ohyashiki K, Ito Y, Hori K, Sato K, Makino T, Ohyashiki JH. Thrombosis can occur at any phase of essential thrombocythemia with JAK2V617F mutation: a single institutional study in Japan. Leukemia. 2007;21:1570–1.
Finazzi G, Rambaldi A, Guerini V, Carobbio A, Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica. 2007;92:135–6.
Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and Jak2 mutation status. Blood. 2007;105:2310–3.
Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459–68.
Tefferi A, Thiele J, Orazi A, et al. Proposals amd rationale for revison of the World Heal Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood. 2007;110:1092–7.
Michiels JJ, De Raeve H, Hebeda K, et al. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloprolierative disorders. Leuk Res. 2007;31:1031–8.
Acknowledgments
Thanks are due to Professor J Patrick Barron of the International Medical Communications Center of Tokyo Medical University for his review of this manuscript. This work was supported in part by the “High-Tech Research Center” Project from the Ministry of Education, Culture, Sports and Technology (MEXT) and by the “University-Industry Joint Research Project” from MEXT. This work has been also supported by Foundation for Promotion of Cancer Research in Japan (JHO).
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Ohyashiki, K., Kiguchi, T., Ito, Y. et al. Leukocytosis is linked to thrombosis at diagnosis, while JAK2 V617F mutation is associated with thrombosis during the course of essential thrombocythemia. Int J Hematol 87, 446–448 (2008). https://doi.org/10.1007/s12185-008-0080-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-008-0080-9